Lumpectomy is not advised if breast cancer returns

A mastectomy is prudent when breast cancer returns after a lumpectomy, because survival rates are higher for those who have another lumpectomy, according to a new study published in the American Journal of Surgery in October.

‘We were surprised to find that so many women in our study – almost a quarter – had received another lumpectomy rather than a mastectomy,’ said Dr Steven L Chen, from the University of California Davis Cancer Centre in Sacramento. ‘It’s likely that patients are asking for lumpectomies when their cancer is diagnosed a second time, and their doctors are simply complying with that request. Whatever the reason, that decision can shorten life spans.’
The study involved 747 women who had a same-breast cancer recurrence after undergoing breast conservation therapy. Of these patients 24% underwent a second lumpectomy. The five-year survival rate was 67% for women who had a lumpectomy compared with 78% for those who had mastectomies. Analysis confirmed that lumpectomy reduced the odds of survival by 50%.
‘As therapy for breast cancer becomes more targeted, and researchers come closer to identifying those factors that make some breast cancers more aggressive than others, we may have the option of recommending second, and even third lumpectomies in select cases in the future,’ said study co-author Dr Steven Martinez. ‘Until then, mastectomy remains the best option for women experiencing a same-breast recurrence of their breast cancer.’

20.11.2008

More on the subject:

Related articles

Photo

Article • Future treaments discussed at senology congress

How will we treat breast cancer in 2034?

The year: 2034. Breast cancer patients benefit from perfectly personalised diagnostics and therapies. The tedium of follow-up treatments is a thing of the past, thanks to AI, augmented reality and…

Photo

Interview • Congress showcases advances

Making immunotherapy work for more cancer patients

Immunotherapy has become the most promising strategy for treating several cancers, but its effectiveness is still very uneven. Three researchers explain how research is being done to change this.

Photo

News • New imaging agent

HER2-positive breast cancer: Whole-body PET/CT predicts targeted therapy response

A new imaging agent can predict early metabolic response to HER2-targeted treatment in metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine.

Related products

Subscribe to Newsletter